Rupatadine 10 mg in adolescent and adult symptom relief of perennial allergic rhinitis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Therapy

• Publication date

  2010-07-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/THY.10.40
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Second-Generation Antihistamines

  2012cited by this paper
• [Allergic rhinitis and its impact on asthma].

  2010cited by this paper
• Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo

  2009cited by this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *

  2008cited by this paper
• A 12‐week placebo‐controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis

  2008cited by this paper
• Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.

  2006cited by this paper
• Histamine in Allergic Inflammation and Immune Modulation

  2005cited by this paper
• Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.

  2005cited by this paper
• Epidemiological characterization of the intermittent and persistent types of allergic rhinitis

  2005cited by this paper
• Prevalence and rate of diagnosis of allergic rhinitis in Europe

  2004cited by this paper
• Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study

  2004cited by this paper
• A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.

  2004cited by this paper
• Antihistamines in late-phase clinical development for allergic disease

  2002cited by this paper
• The effect of platelet‐activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide

  2000cited by this paper
• Pathogenic Mechanisms Underlying the Clinical Symptoms of Allergic Rhinitis

  2000cited by this paper
• H1-receptor antagonists: safety issues.

  1999cited by this paper
• Pharmacologic management of allergic rhinitis.

  1998cited by this paper
• Management of rhinitis – the specialist’s opinion

  1998cited by this paper
• Management of rhinitis – the specialist’s opinion

  1998cited by this paper
• Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases.

  1998cited by this paper
• Mediators of nasal blockage in allergic rhinitis.

  1997cited by this paper
• Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).

  1997cited by this paper
• Contribution of platelet activating factor (PAF) in histamine-induced model of nasal allergy in rats.

  1995cited by this paper
• Asthma and Allergic Rhinitis among Finnish Adolescents in 1977–1991

  1995cited by this paper
• Soluble markers of allergic inflammation

  1994cited by this paper
• Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor.

  1994cited by this paper
• International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group.

  1994cited by this paper
• The effects of anti-PAF and other agents on the nasal symptoms in sensitized guinea pigs.

  1993cited by this paper
• Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells.

  1992cited by this paper
• Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig.

  1989cited by this paper
• Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs.

  1988cited by this paper
• Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.

  1985cited by this paper

• Efficacy of different oral H1 antihistamine treatments on allergic rhinitis: a systematic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans.

  2021cites this paper
• Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis

  2020cites this paper
• Update on rupatadine in the management of allergic disorders

  2015cites this paper
• Rupatadine for the treatment of allergic rhinitis and urticaria: a look at the clinical data

  2014cites this paper
• Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis

  2013influential citation